[1]Schirinzi T, Di Lazzaro G, Sancesario G M, et al. Young-onset and late-onset Parkinson's disease exhibit a different profile of fluid biomarkers and clinical features[J]. Neurobiol Aging, 2020, 90: 119-124.
[2]Mehanna R, Jankovic J. Young-onset Parkinson's disease: its unique features and their impact on quality of life[J]. Parkinsonism Relat Disord, 2019, 65: 39-48.
[3]Camerucci E, Stang C D, Hajeb M, et al. Early-onset parkinsonism and early-onset Parkinson's disease: a population-based study (2010-2015)[J]. J Parkinsons Dis, 2021, 11(3): 1197-1207.
[4]Chahine L M, Beach T G, Brumm M C, et al. In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease[J]. Neurology, 2020, 95(9): e1267-e1284.
[5]Barbour R, Kling K, Anderson J P, et al. Red blood cells are the major source of α-synuclein in blood[J]. Neurodegener Dis, 2008, 5(2): 55-59.
[6]Wang X M, Yu S, Li F F, et al. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease[J]. Neurosci Lett, 2015, 599: 115-119.
[7]Liu G L, Yu Z W, Gao L Y, et al. Erythrocytic α-synuclein in early Parkinson's disease: a 3-year longitudinal study[J]. Parkinsonism Relat Disord, 2022, 104: 44-48.
[8]Postuma R B, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease[J]. Mov Disord, 2015, 30(12): 1591-1601.
[9]Bloem B R, Okun M S, Klein C. Parkinson's disease[J]. Lancet, 2021, 397(10291): 2284-2303.
[10]Zheng Y C, Yu Z W, Zhao J J, et al. Oral mucosa derived α-synuclein as a potential diagnostic biomarker for Parkinson's disease[J]. Front Aging Neurosci, 2022, 14: 867528.
[11]Niu M, Li Y, Li G, et al. A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression[J]. Eur J Neurol, 2020, 27(6): 967-974.
[12]Simuni T, Siderowf A, Lasch S, et al. Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort[J]. Mov Disord, 2018, 33(5): 771-782.
[13]Liu S Y, Wu J J, Zhao J, et al. Onset-related subtypes of Parkinsons disease differ in the patterns of striatal dopaminergic dysfunction: a positron emission tomography study[J]. Parkinsonism Relat Disord, 2015, 21(12): 1448-1453.
[14]Li X Y, Li W, Li X, et al. Alterations of erythrocytic phosphorylated α-synuclein in different subtypes and stages of Parkinson's disease[J]. Front Aging Neurosci, 2021, 13: 623977.
[15]Parnetti L, Gaetani L, Eusebi P, et al. CSF and blood biomarkers for Parkinson's disease[J]. Lancet Neurol, 2019, 18(6): 573-586.
[16]Hall S, Surova Y, Öhrfelt A, et al. Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson's disease[J]. Mov Disord, 2016, 31(6): 898-905.
[17]Kalia L V. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid[J]. Parkinsonism Relat Disord, 2019, 59: 21-25.
|